BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17477035)

  • 1. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Chen YC; Lu SN; Lin MC
    Chang Gung Med J; 2007; 30(1):92-7. PubMed ID: 17477035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
    Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N
    Ann Hepatol; 2008; 7(1):87-90. PubMed ID: 18376374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
    Rothfuss KS; Bode JC
    Z Gastroenterol; 2002 Sep; 40(9):807-10. PubMed ID: 12215950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
    Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report.
    Tamaki K; Okubo A
    World J Gastroenterol; 2015 Jan; 21(3):1009-13. PubMed ID: 25624738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.
    Slavenburg S; Heijdra YF; Drenth JP
    Dig Dis Sci; 2010 Mar; 55(3):579-85. PubMed ID: 19399621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
    Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.
    Alves Couto C; Costa Faria L; Dias Ribeiro D; de Paula Farah K; de Melo Couto OF; de Abreu Ferrari TC
    Liver Int; 2006 Dec; 26(10):1294-7. PubMed ID: 17105597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Respiratory function impairment during treatment of chronic hepatitis C with peginterferon alfa2 and ribavirin. Two cases presentation].
    Biedroń-Machura M; Musialik J; Sozańska E; Zbroszczyk M; Baron J; Błońska-Fajfrowska B; Pierzchała W
    Wiad Lek; 2012; 65(4):232-8. PubMed ID: 23654144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial pneumonitis after treatment for hepatitis C virus infection.
    Botnaru V; Munteanu O; Rusu D
    Pneumologia; 2015; 64(1):46-50. PubMed ID: 26016056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
    Iacob SA; Petrescu AM; Iacob DG
    Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
    Abergel A; Hezode C; Leroy V; Barange K; Bronowicki JP; Tran A; Alric L; Castera L; Bernard PH; Henquell C; Lafeuille H; Ughetto S; Darcha C; Chevallier M; Martineau N; Dubost S; Randl K; Dhumeaux D; Bommelaer G; Bonny C;
    J Viral Hepat; 2006 Dec; 13(12):811-20. PubMed ID: 17109680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.
    Karim A; Ahmed S; Khan A; Steinberg H; Mattana J
    Am J Med Sci; 2001 Oct; 322(4):233-5. PubMed ID: 11678522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
    Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.